Regulatory approaches to new psychoactive substances (NPS) in the European Union

Addiction

Volumn 109, Issue 10, 2014, Pages 1591-1593

  Hughes, Brendan ^a   Griffiths, Paul ^a  

^a EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

Drugs; Europe; Legislation; NPS; Policy; Regulation

Indexed keywords

PSYCHOTROPIC AGENT;

DRUG CONTROL; DRUG LEGISLATION; EUROPEAN UNION; HUMAN; LEGISLATION AND JURISPRUDENCE; NEW ZEALAND; SUPPLY AND DISTRIBUTION;

DRUG AND NARCOTIC CONTROL; EUROPEAN UNION; HUMANS; LEGISLATION, DRUG; NEW ZEALAND; PSYCHOTROPIC DRUGS;

EID: 84906751133     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12610     Document Type: Article

References (17)

1. Wilkins C. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand. Addiction 2014; 109: 1580-1586.
2. European Commission. Proposal for a Regulation of the European Parliament and of the Council on new psychoactive substances. 2013. COM(2013) 619. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2013:0619:FIN:en:PDF (accessed 11 April 2014) (Archived at http://www.webcitation.org/6OkigCagB on 11 April 2014).
3. Newberry J., Wodak A., Sellman D., Robinson G. New Zealand's regulation of new psychoactive substances. BMJ 2014; 348: g1534.
4. Baker N. Drugs policy: new psychoactive substances. 2014. Available at: https://www.gov.uk/government/speeches/drugs-policy-new-psychoactive-substances--2 (accessed 11 April 2014) (Archived at http://www.webcitation.org/6OkikxBD4 on 11 April 2014).
5. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Europol. EMCDDA-Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA. Luxembourg: Publications Office of the European Union; 2013.
6. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Europol. EU drug markets report: a strategic analysis. Luxembourg: Publications Office of the European Union; 2013.
7. Griffiths P., Evans-Brown M., Sedefov R. Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age. Addiction 2013; 108: 1700-1703.
8. Reuter P. Options for regulating new psychoactive drugs: a review of recent experiences: UK Drug Policy Commission (UKDPC). London: UKDPC, 2011.
9. May T. Letter to ACMD on control of khat. 2013; Home Office. Available at: https://www.gov.uk/government/publications/letter-to-acmd-on-control-of-khat (accessed 11 April 2014) (Archived at http://www.webcitation.org/6OkiouSvP on 11 April 2014).
10. Van Laar M., Cruts G., van Gageldonk A., van Ooyen-Houben M., Croes E., Meijer R. etal. Report to the EMCDDA by the Reitox National Focal Point. 2008. Available at: http://www.emcdda.europa.eu/html.cfm/index86748EN.html (accessed 11 April 2014) (Archived at http://www.webcitation.org/6Okira9lw on 11 April 2014).
11. MacCoun R., Reuter P. The implicit rules of evidence-based drug policy: a US perspective. Int J Drug Policy 2008; 19: 231-232.
12. Home Affairs Committee. Drugs: new psychoactive substances and prescription drugs. Twelfth Report of Session 2013-14. 2013; HC819: p12.
13. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Legal approaches to controlling new psychoactive substances. 2014. Available at: http://www.emcdda.europa.eu/topics/pods/controlling-new-psychoactive-substances (accessed 11 April 2014) (Archived at http://www.webcitation.org/6Okiup0z3 on 11 April 2014).
14. Hughes B., Winstock A. R. Controlling new drugs under marketing regulations. Addiction 2012; 107: 1894-1899.
15. Ryall G., Butler S. The great Irish head shop controversy. Drugs Educ Prev Policy 2011; 18: 303-311.
16. Hughes B., Winstock A. Consumer safety in the public interest. Addiction 2012; 107: 2054-2055.
17. Tribunal Constitucional. Acórdão do Tribunal Constitucional [Judgement of the Constitutional Court] n.° 397/2012. Diário da República, 1. série-N.° 178-13 de setembro de 2012, p5207.